Chief, Division of Neurosciences Critical Care
Associate Professor of Anesthesiology and Critical Care Medicine
Associate Professor of Neurology
Associate Professor of Neurological Surgery
The Johns Hopkins University School of Medicine
600 N. Wolfe Street, Meyer 8-140
Baltimore, MD 21287
Dr. J. Ricardo Carhuapoma’s overall research interests include three areas: (1) the role of pharmacologic neuroprotection of perihematoma tissue following intracerebral hemorrhage (ICH); (2) the different hemodynamic and metabolic aspects of neuronal blood flow and metabolism under physiologic conditions and after acute brain injury, as well as their significance in neurologic outcome; and (3) the use of advanced MRI techniques in the study and understanding of ongoing neuronal damage after brain injury to design and assess therapies used in neurologic critical care.
To investigate these areas, Dr. Carhuapoma is engaged in a number of studies. The first explores the safety and feasibility of thrombolysis with ultrasound in the treatment of ICH and intraventricular hemorrhage (known as the SLEUTH study).
In another study, Dr. Carhuapoma and his colleagues are investigating removal of an ICH with minimally invasive surgery and treatment with recombinant tissue plasminogen activator (rtPA). The goal of this study is to provide novel safety data that will change the way in which ICHs are treated, including previously unavailable data about the safety, efficacy, and pharmacokinetics of rtPA, as well as MIS data regarding the validity and safety of patient selection, quantitation of surgical effectiveness, patient stability, and disease/treatment-related complications. The study results also will provide the first estimates of the relationship between initial disease severity and long-term outcome for ICH. These data are critical to reducing brain injury from the only stroke subtype for which no adequate treatment is available.
In a study supported by the Food & Drug Administration, Dr. Carhuapoma and his colleagues are conducting a multicentered clinical trial of thrombolysis for intraventricular hemorrhage, the results of which will allow for the development of an effective treatment for intraventricular hemorrhage and demonstrate the safety and efficacy of thrombolysis with rtPA for that type of stroke.